MVA Technology

A drop of human blood is presumed to have 1011 specific antibodies that recognize different immunogens (natural antigen epitopes and antigenic mimics, mimotopes). Although the potential size of the human immunoglobulin repertoire has been estimated, the understanding of its overall involvement in the immune response has remained elusive, mainly because we are not yet able to decipher it. MVA technology has overcome that problem. Protobios' novel technology platform, Mimotope Variation Analysis (MVA, patent pending), for parallel and quantitative profiling of the binding specificity, versatility and biological activity of millions of antibodies, reflects the total immune response.


MVA technology enables to obtain quantitative and qualitative antibody binding profiles (immunoprofiles). A binding profile can be made to describe a single molecule up to individuals or populations. An immunoprofile describes the state of the immune system and its ability to protect the body. That is considered an innovative tool interpreting health related data for diseases; health conditions and propels the caregivers towards a new level of understanding regarding the prevention and treatment. Also MVA allows offering reliable services such as epitope mapping, antibody analyses, immunogenicity assessment etc. to research groups and biotechnology industry.


MVA technology is based on screening of combinatorial peptide display library, next generation DNA sequencing and proprietary bioinformatics analysis.


Changes in the antibody binding profile (ABP) enable us to detect early signs of disease. The results of our analysis and published data clearly show that ABPs can be used to characterize a person’s health status, and specific ABP “snapshots” (antibodies with definite binding specificity) can be used as disease-specific biomarkers for development of specific diagnostic tests.


In antibody development (both therapeutic and diagnostic), MVA can be used to define the epitope in the peptide antigen that is responsible for antibody binding. Use of MVA also helps to accelerate the development of antibodies possessing the appropriate epitopes for binding.


Analyses of the ABPs of approximately 2000 human blood samples using MVA technology clearly showed that immunoprofiles contain signatures generated by exposure to major pathogens, to vaccinations (HPV and flu vaccines trials), and a vast number of disease and health condition-related patterns that are person-specific and relatively stable over time (months and years). Changes in the immunoprofile reveal differences between the expected response to vaccines or therapeutic proteins and potential side effects.


Another application of MVA is the profiling of multi-pathogen infections which improves the efficiency of screening programs, as use of MVA based multiplex tests would be a strong competitor to one pathogen specific tests. Cost effective and consumer friendly Point of Care tests, developed based on immunoprofiles, would yield an additional bonus by revealing more data for the user/screening program, creating a chance for the early diagnoses of more diseases or concurrently offering some relief to the medical system.


In addition to medicine, MVA can be used in veterinary medicine to develop novel diagnostic tools and to validate the health of animals. Also, MVA can be used for environmental monitoring and analysis of diseases in different ecosystems. Since ABPs are relatively stable over time, this approach can be used in forensics to identify individuals and their habits and travel routes